OpenCareby Vivonco
Search/
Talk to us Review a case
Menu
Skip to content
No. 38 · Monday, November 16, 2026

The antibody-drug conjugate sacituzumab tirumotecan combo slowed advanced lung cancer

  1. The antibody-drug conjugate sacituzumab tirumotecan combo slowed advanced lung cancer
  2. PD-1 immunotherapy studied after surgery for several cancers
  3. AI tool improved predictions from cancer tissue slides
  4. A blood test predicted survival with prostate cancer radioligand treatment
Read this first · Phase III trial · lung cancer

The antibody-drug conjugate sacituzumab tirumotecan combo slowed advanced lung cancer

People with newly diagnosed advanced lung cancer received the antibody-drug conjugate sacituzumab tirumotecan with the immunotherapy pembrolizumab. The cancer took a median 15 months to grow, versus 5.7 months with chemotherapy and pembrolizumab.

Why it matters. People with advanced lung cancer without targetable changes may have more time before their cancer grows with this combination. Results from a large final-stage trial like this decide approvals.

Cancer Discovery, 14 Nov 2026 · Phase III human clinical trial Worth sharing · Share on X · Email a friend
Phase II trial · several cancer types

PD-1 immunotherapy studied after surgery for several cancers

People with several types of early-stage cancer received six months of PD-1 immunotherapy with pembrolizumab after a blood test found signs of leftover cancer. The test became negative in 11 of 13 people, but five had a recurrence.

“These findings provide evidence that ctDNA-guided adjuvant therapy (given after surgery) may offer clinical benefit in dMMR tumors regardless of tissue of origin.”

Why it matters. People with several types of cancer after surgery may one day get immunotherapy guided by a blood test for leftover cancer. A larger trial usually comes before approval.

Annals of Oncology, 13 Nov 2026 · Phase II human clinical trial | 184 patients Worth sharing · Share on X · Email a friend
Research

AI tool improved predictions from cancer tissue slides

Researchers tested Hist2Prot, an artificial intelligence tool that predicts protein patterns from routine cancer slides, across seven patient groups. Its predictions improved estimates of cancer outcomes and response to immunotherapy for 1,774 patients.

Why it matters. People with cancer may get better predictions about how their disease will progress and whether immunotherapy may help. It studied patient records rather than testing a treatment.

Nature Cancer, 13 Nov 2026 · Human observational study | 1,774 patients
Research · prostate cancer

A blood test predicted survival with prostate cancer radioligand treatment

Researchers reviewed 501 people with advanced prostate cancer who received radioligand treatment after taxane therapy. A ratio of two types of blood cells above 3 predicted poorer survival, especially when it stayed high at the next treatment cycle.

“NLR > 3 is an adverse prognostic factor in patients receiving LuPSMA, and early NLR dynamics may be helpful in identifying patients who require closer disease monitoring during therapy.”

Why it matters. People with advanced prostate cancer receiving radioligand treatment may get closer monitoring if their blood test ratio stays high. It studied patient records rather than testing a treatment.

Prostate Cancer and Prostatic Diseases, 14 Nov 2026 · Human observational study | 501 patients

Deals and stopped trials

Worth watching